Upgrade to SI Premium - Free Trial

Trillium Therapeutics (TRIL) Says TTI-2341 EGFR Inhibitor Program Featured at SNO Meeting

November 20, 2017 7:06 AM
Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles